IRF4 Mediates Immune Evasion to Facilitate EBV Transformation

QR Code

IRF4 Mediates Immune Evasion to Facilitate EBV Transformation

The lymphocyte-specific transcription factor interferon regulatory factor 4 (IRF4) is a key player in immune evasion in cancers, with the complex mechanism(s) being barely understood. In this study, we have focused on the role of IRF4 in regulating T cell functions through its transcriptional regula...

Full description

Saved in:

Bibliographic Details
Main Authors:	Ling Wang, Culton R. Hensley, Jahan Rifat, Adam D. Walker, Katharine Ning, Jonathan P. Moorman, Zhi Q. Yao, Shunbin Ning
Format:	Article
Language:	English
Published:	MDPI AG 2025-06-01
Series:	Viruses
Subjects:	IRF4 EBV PD1 PD-L1
Online Access:	https://www.mdpi.com/1999-4915/17/7/885
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

IRF1 amplifies HSV-1-triggered antiviral innate immunity in a feed-forward manner
by: Ming Gao, et al.
Published: (2025-08-01)

Activity of Negative Regulation of the PD-1/PD-L1/PD-L2 T-Cell Response System in Patients with Pneumonia and Inﬂuenza A (H1N1)
by: A. V. Malyarchikov, et al.
Published: (2021-08-01)

Ginseng-Derived Exosomes Attenuate Immune Evasion in NSCLC via PD-L1 Modulation
by: Zhu LJ, et al.
Published: (2025-07-01)

Modern possibilities of using immunotherapy in the treatment of cervical cancer
by: A. V. Tarasova, et al.
Published: (2021-09-01)

Programmed death‐ligand 1 expression in swine chronic infections and enhancement of interleukin‐2 production via programmed death‐1/programmed death‐ligand 1 blockade
by: Otgontuya Ganbaatar, et al.
Published: (2021-12-01)

Synthesis and Evaluation of [<sup>18</sup>F]AlF-NOTA-iPD-L1 as a Potential Theranostic Pair for [<sup>177</sup>Lu]Lu-DOTA-iPD-L1
by: Guillermina Ferro-Flores, et al.
Published: (2025-07-01)

Visualization of PD-L1-positive and PD-1-positive immune cell contact in the breast cancer microenvironment
by: A. Yu. Kalinchuk, et al.
Published: (2024-03-01)

Clinical efficacy and safety of anti-PD-1/PD-L1 treatments in non-small cell lung cancer (NSCLC)
by: Tian Zeng, et al.
Published: (2019-12-01)

Relationship between the expressions of PD-L1 and tumour-associated fibroblasts in gastric cancer
by: Linsong Mu, et al.
Published: (2019-12-01)

Dynamics of REL, RELA and IRF1 transcription factor expression in U937 macrophages after dioxin exposure
by: E. V. Kashina, et al.
Published: (2017-02-01)

Current Advances and Future Directions for Sensitizing Gastric Cancer to Immune Checkpoint Inhibitors
by: Wenke Li, et al.
Published: (2025-07-01)

Enhancing CAR-T Efficacy: The Role of Anti PD-1/PD-L1 Checkpoint Inhibitors in Modern Cancer Treatment
by: Rishi Kant, et al.
Published: (2025-06-01)

Involvement of the Programmed Death 1/Programmed Death Ligand 1 Pathway in the Immune Microenvironment of Chronic Periapical Lesions
by: Yujin Song, et al.
Published: (2025-08-01)

ROLE OF PD-L1 ASSESSMENT IN THE ASPECT OF MOLECULAR-GENETIC CLASSIFICATION OF COLORECTAL CANCER. CURRENT STATE OF THE PROBLEM
by: S. V. Vtorushin, et al.
Published: (2021-03-01)

Cancer therapeutic implications of microRNAs in the regulation of immune checkpoint blockade
by: Yan Zhang, et al.
Published: (2019-08-01)

A novel short transcript isoform of chicken IRF7 negatively regulates interferon-β production
by: Yu-chen MA, et al.
Published: (2023-07-01)

Combined radiation and immune checkpoint inhibitor therapy for metastatic or recurrent hepatocellular carcinoma: a real-world study of 108 patients
by: Yirui Zhai, et al.
Published: (2025-08-01)

MODERN POSSIBILITIES OF THERAPY WITH INHIBITORS OF CONTROL POINTS IN METASTATIC UROTHELIAL CANCER
by: R. A. Gafanov, et al.
Published: (2018-03-01)

Integrating clinical trial landscapes and bibliometric analysis: unveiling the impact of PD-1/PD-L1 inhibitors on renal cell carcinoma research and therapeutic trajectories summary
by: Yuanbin Huang, et al.
Published: (2025-07-01)

Spotlight on nuclear PD-L1 in ovarian cancer chemoresistance: hidden but mighty
by: Meshach Asare-Werehene, et al.
Published: (2025-07-01)

Nivolumab-containing therapy in patients with newly diagnosed classical Hodgkin lymphoma: own clinical observations and literature review
by: D. D. Ivanova, et al.
Published: (2024-12-01)

Metabolism of tryptophan in non-small lung cancer patients with different effect of PD-1 / PD-L1 inhibitors immunotherapy
by: E. Yu. Zlatnik, et al.
Published: (2022-06-01)

PREDICTIVE RESPONSE MARKERS FOR IMMUNE RESPONSE BLOCKS
by: G. A. Janus, et al.
Published: (2020-09-01)

Clinical observation of the efficacy of PD‐1/PD‐L1 inhibitors in the treatment of patients with advanced solid tumors
by: Miao Wang, et al.
Published: (2021-12-01)

The regulatory effects of PD-1/PD-L1 inhibitors on bone metabolism: opportunities and challenges in osteoporosis management
by: Jia-Wen Wang, et al.
Published: (2025-07-01)

Bimodal onset and pan-cancer uniformity of immune-mediated liver injury: a retrospective cohort study
by: Jiaojiao Song, et al.
Published: (2025-07-01)

Mapping the immunological landscape and emerging immunotherapeutic strategies in cervical cancer: a comprehensive review
by: Xinyi Zhang, et al.
Published: (2025-07-01)

Receptor occupancy assessment and interpretation in terms of quantitative systems pharmacology: nivolumab case study
by: Dmitry Shchelokov, et al.
Published: (2023-12-01)

Current trends in the immunotherapy of metastatic and recurrent squamous cell carcinoma of the head and neck
by: Yu. V. Kostalanova, et al.
Published: (2020-11-01)

STUDENT INITIATED DEPARTURES FROM THE INITIATION-RESPONSE-FEEDBACK (IRF) FORMAT
by: Natalya V. Vesnina
Published: (2019-06-01)

Ligand-associated activation of vitamin D receptors and potential points of application of its effects in the morphogenesis of immune inflammation: Literature review
by: E. T. Ablyakimov, et al.
Published: (2024-07-01)

Development and Validation of a Biolayer Interferometry Method for Determination of Human Anti-PD-1 Monoclonal Antibody Concentration in Cynomolgus Serum
by: K. V. Ulyanova, et al.
Published: (2020-12-01)

Prognostic significance of PD-L1 expression and evaluation of microsatellite instability status in patients with retroperitoneal leiomyosarcomas
by: V. Е. Bugaev, et al.
Published: (2019-11-01)

Advances in the structural characterization of complexes of therapeutic antibodies with PD-1 or PD-L1
by: Mengzhen Jiang, et al.
Published: (2023-12-01)

The predictive value of total body PET/CT in high PD-L1 expression and immunotherapy in advanced non-small cell lung cancer patients
by: Huibin Jin, et al.
Published: (2025-07-01)

Male Sex as a Predictor of Worse Prognosis and Clinical Evolution in Patients with Cancer and SARS-CoV-2 Infection, Independent of the rs41386349 <i>PDCD1</i> Polymorphism
by: Caroline Yukari Motoori Fernandes, et al.
Published: (2025-07-01)

Evaluation of the Effectiveness and Safety Profile of First-Line Immune Checkpoint Inhibitors Combined with Chemotherapy in Pulmonary Sarcomatoid Carcinoma
by: Du H, et al.
Published: (2025-06-01)

Epigenetic modifiers to enhance the efficacy of immune checkpoint inhibitors for the treatment of melanoma
by: Luigi Liguori, et al.
Published: (2025-09-01)

LncRNA BACE1-AS delays the propagation of Cryptosporidium parvum through regulating cell apoptosis by targeting the miR-6805-5p/IRF3 axis
by: Shuang Huang, et al.
Published: (2025-07-01)

The influence of H. pylori infection in HER2-positive gastric cancer cell lines: insights from Wnt/β-catenin pathway
by: Valli De Re, et al.
Published: (2025-06-01)